Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta‐analysis
Clinical Cardiology · 2023
DOI: 10.1002/clc.24011 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Cardiology, 2023. Verfasst von Jagmeet P Singh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Amiodarone, Atrial Fibrillation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Background
There are limited comparative data on safety and efficacy within commonly used Vaughan‐Williams (VW) class III antiarrhythmic drugs (AADs) for maintenance of sinus rhythm in adults with atrial fibrillation (AF). Hypothesis We hypothesized that dronedarone and sotalol, two commonly prescribed VW class III AADs with class II properties, have different safety and efficacy effects in patients with nonpermanent AF.
Methods
A systematic literature review was conducted searching MEDLINE®, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to June 15, 2021 (NCT05279833). Clinical trials and observational studies that evaluated safety and efficacy of dronedarone or sotalol in adults with AF were included. Bayesian random‐effects network meta‐analysis (NMA) was used to quantify comparative safety and efficacy. Where feasible, we performed sensitivity analyses by including only randomized controlled trials (RCTs).
Results
Of 3581 records identified through database searches, 37 unique studies (23 RCTs, 13 observational studies, and 1 nonrandomized trial) were included in the NMA. Dronedarone was associated with a statistically significantly lower risk of all‐cause death versus sotalol (hazard ratio [HR] = 0.38 [95% credible interval, CrI: 0.19, 0.74]). The association was numerically similar in the sensitivity analysis (HR = 0.46 [95% CrI: 0.21, 1.02]). AF recurrence and cardiovascular death results were not significantly different between dronedarone and sotalol in all‐studies and sensitivity analyses.
Conclusion
The NMA findings indicate that, across all clinical trials and observational studies included, dronedarone compared with sotalol was associated with a lower risk of all‐cause death, but with no difference in AF recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Division, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Cardiology, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Department of Medical Science, Uppsala University, Uppsala, Sweden.
- Department of Medicine (Cardiovascular Medicine), Center for Digital Health, Stanford University, Stanford, California, USA.
- Cardiac Academic Group, St. George's University of London, London, UK.
- Evidinno Outcomes Research Inc., Vancouver, Canada.
Förderung
- Sanofi
Zitieren
APA
Singh, J. P., Blomström-Lundqvist, C., Turakhia, M. P., Camm, A. J., Fazeli, M. S., Kreidieh, B., Crotty, C., & Kowey, P. R. (2023). Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta‐analysis. Clinical Cardiology. https://doi.org/10.1002/clc.24011
Vancouver
Singh JP, Blomström-Lundqvist C, Turakhia MP, Camm AJ, Fazeli MS, Kreidieh B, et al. Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta‐analysis. Clinical Cardiology. 2023. doi:10.1002/clc.24011
BibTeX
@article{Singh2023,
author = {Singh, Jagmeet P and Blomström-Lundqvist, Carina and Turakhia, Mintu P and Camm, A John and Fazeli, Mir Sohail and Kreidieh, Bahij and Crotty, Christopher and Kowey, Peter R},
title = {Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta‐analysis},
journal = {Clinical Cardiology},
year = {2023},
doi = {10.1002/clc.24011}
}
EUVIMED